Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect.

Authors:
Esther R van Bladel Mariëtte J Agterof Bernard D Frijling René van der Griend Martin H Prins Roger E G Schutgens Douwe H Biesma

Thromb Res 2010 Dec;126(6):481-5

Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.

Introduction: Traditionally, patients with pulmonary embolism (PE) are treated in-hospital until they reach an adequate international normalized ratio (INR). Analogous to patients with a deep venous thrombosis, therapy with low-molecular-weight heparin facilitates out of hospital treatment of PE. We retrospectively analysed the current practice of early anticoagulant therapy in 86 acute PE patients with emphasis on the occurrence and safety of outpatient treatment.

Methods: Data were collected from two large regional teaching hospitals and from a specialized anticoagulation clinical, where patients were followed in the period after hospital discharge. The course of hospitalization and LMWH transitioning therapy and the quality of treatment in the first three months after diagnosis were compared between patients discharged before and patients discharged after reaching adequate INR.

Results: Forty-four patients (51.2%) were discharged early, before reaching an adequate INR, and 42 patients (48.8%) were discharged after reaching adequate INR. Early discharged patients needed more time to reach adequate INR compared to other patients (13 versus 6 days). In 28 patients (32.6%), the LMWH transitioning therapy was stopped prematurely; 21 patients were from the early discharged group. During the first 3 months, the mean individual times below, in and above the INR range were equal between the two groups.

Conclusion: Enhanced compliance to existing guidelines and tools, and further development of guidelines, with focus on intensification of monitoring of INR values in an outpatient setting and preventing premature discontinuation of transitioning therapy, are warranted for a safe and early discharge of stable patients with PE.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2010.08.019DOI Listing
December 2010

Publication Analysis

Top Keywords

patients
14
reaching adequate
12
adequate inr
12
transitioning therapy
12
patients discharged
8
compared patients
8
discharged patients
8
pulmonary embolism
8
reach adequate
8
anticoagulant therapy
8
discharged reaching
8
lmwh transitioning
8
early discharged
8
inr
6
discharged
6
therapy
6
early
5
adequate
5
hospitals specialized
4
early reaching
4

Keyword Occurance

Similar Publications

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.

Authors:
Gregory K Friedman James M Johnston Asim K Bag Joshua D Bernstock Rong Li Inmaculada Aban Kara Kachurak Li Nan Kyung-Don Kang Stacie Totsch Charles Schlappi Allison M Martin Devang Pastakia Rene McNall-Knapp Sameer Farouk Sait Yasmin Khakoo Matthias A Karajannis Karina Woodling Joshua D Palmer Diana S Osorio Jeffrey Leonard Mohamed S Abdelbaki Avi Madan-Swain T Prescott Atkinson Richard J Whitley John B Fiveash James M Markert G Yancey Gillespie

N Engl J Med 2021 Apr 10. Epub 2021 Apr 10.

From the Department of Pediatrics, Divisions of Pediatric Hematology-Oncology (G.K.F., K.K., L.N., K.-D.K., S.T., C.S., A.M.-S.), Pediatric Allergy and Immunology (T.P.A.), and Pediatric Infectious Disease (R.J.W.), and the Departments of Neurosurgery (G.K.F., J.M.J., J.M.M., G.Y.G.), Pathology (R.L.), Biostatistics (I.A.), and Radiation Oncology (J.B.F.), University of Alabama at Birmingham, and Children's of Alabama (G.K.F., J.M.J., R.L., K.K., A.M.-S., T.P.A., R.J.W.) - both in Birmingham; the Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis (A.K.B.), and the Department of Pediatrics, Vanderbilt University Medical Center, Nashville (D.P.) - both in Tennessee; the Department of Neurosurgery, Brigham and Women's Hospital and Boston Children's Hospital, Harvard Medical School, Boston (J.D.B.); the Department of Pediatrics, Albert Einstein College of Medicine (A.M.M.), and the Departments of Pediatrics (S.F.S., Y.K., M.A.K.) and Neurology (Y.K.), Memorial Sloan Kettering Cancer Center - both in New York; the Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City (R.M.-K.); the Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant (K.W., D.S.O., M.S.A.) and the Department of Pediatric Neurosurgery (J.L.), Nationwide Children's Hospital, and the Department of Radiation Oncology, Ohio State University Comprehensive Cancer Center (J.D.P.) - both in Columbus; and the Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant, Washington University School of Medicine, St. Louis (M.S.A.).

Background: Outcomes in children and adolescents with recurrent or progressive high-grade glioma are poor, with a historical median overall survival of 5.6 months. Pediatric high-grade gliomas are largely immunologically silent or "cold," with few tumor-infiltrating lymphocytes. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Vagus nerve stimulation does not alter brainstem nuclei morphology in patients with refractory epilepsy.

Authors:
Jane J Ding Peter Liu Hillary Rebernig Ana Suller-Marti Andrew G Parrent Jorge G Burneo Robert R Hammond Lee-Cyn Ang Qi Zhang

Epilepsy Behav 2021 Apr 7;118:107940. Epub 2021 Apr 7.

Department of Clinical Neurological Sciences, London Health Sciences Centre, Western University, London, Ontario, Canada; Department of Pathology and Lab Medicine, London Health Sciences Centre, Western University, London, Ontario, Canada. Electronic address:

Objective: To describe morphological characteristics of the brainstem nuclei in response to chronic vagus nerve stimulation (VNS) in patients with refractory epilepsy.

Background: VNS is a treatment option for individuals with medically refractory epilepsy. While treatment with VNS may achieve up to 50% seizure reduction and is protective against sudden unexpected death in epilepsy (SUDEP), its mechanism of action is not fully understood. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Risks of ACTH therapy for West syndrome following BCG vaccination.

Authors:
Yuki Maki Jun Natsume Ikumi Hori Tomoya Takeuchi Yutaka Negishi Tetsuo Kubota Koichi Maruyama Tomohiko Nakata Hiroyuki Yamamoto Masaharu Tanaka Masahiro Kawaguchi Takeshi Suzuki Anna Shiraki Fumi Sawamura Hiroyuki Kidokoro

Epilepsy Behav 2021 Apr 7;118:107924. Epub 2021 Apr 7.

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Objective: Bacille de Calmette et Guérin (BCG) is a live vaccine for tuberculosis that is administered to all infants in Japan. Adrenocorticotropic hormone (ACTH) therapy for West syndrome (WS) causes immunosuppression and may result in BCG infection after BCG vaccination. We evaluated the safety of ACTH therapy initiated shortly after BCG vaccination. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.

Authors:
Iis Inayati Rakhmat Yudith Yunia Kusmala Dewi Ratih Handayani Henny Juliastuti Eka Noneng Nawangsih Arief Wibowo Michael Anthonius Lim Raymond Pranata

Diabetes Metab Syndr 2021 Apr 1;15(3):777-782. Epub 2021 Apr 1.

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia. Electronic address:

Background And Aims: This study aims to synthesize evidence on dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in COVID-19 patients and factors affecting it.

Methods: We performed a systematic literature search from PubMed, Scopus, and Embase databases from inception of databases up until 7 March 2021. Studies that met all of the following criteria were included: 1) observational studies or randomized controlled trials that report COVID-19 patients, 2) reporting DPP-4 inhibitor use, 3) mortality, and 4) mortality based on DPP-4 inhibitor use. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer.

Authors:
F Schettini P Barbao F Brasó-Maristany P Galván D Martínez L Paré S De Placido A Prat S Guedan

ESMO Open 2021 Apr 7;6(3):100102. Epub 2021 Apr 7.

Department of Hematology, Hospital Clinic, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. Electronic address:

Background: Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody-drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal tissues. To identify new targets for ADCs and CAR-T specifically targeting breast cancer (BC) molecular and pathology-based subtypes, we propose a novel in silico strategy based on multiple publicly available datasets and provide a comprehensive explanation of the workflow for a further implementation. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap